← Eichor
Condition: Ras Mutated Metastatic Colorectal Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ras Mutated Metastatic Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS
Phase 2 · 1 location(s) · Fudan University · NCT06218810Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Revolution Medicines, Inc. · NCT07397338cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224815ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Phase 2 · 1 location(s) · Beijing Hospital · NCT06321081Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06449989Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06763029Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
NA · 37 location(s) · Technische Universität Dresden · NCT04678583Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Pa
Phase 2 · 1 location(s) · Sergey Orlov, MD · NCT06949982Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-me
Phase 3 · 1 location(s) · Caigang Liu · NCT06566755Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224841FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevaciz
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05727163STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT07213570A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Verastem, Inc. · NCT07020221Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/Phase 2 · 32 location(s) · Revolution Medicines, Inc. · NCT06445062
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.